Physician profile
Vincent Macaluso
NPI 1700996758
$92,554.38
in general payments reported to CMS, 2019-2025
18 companies · $72.18 in 2025
The $72.18 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $30K · 2021: $9,291 · 2022: $12K · 2023: $1,847 · 2024: $1,336 · 2025: $72.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.66 |
| Education | $104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $59,724.94 | 2019-2024 | Tysabri, Vumerity |
| Mallinckrodt Enterprises LLC | $14,124.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $9,275.49 | 2020-2024 | Acthar |
| Celgene Corporation | $5,793.68 | 2019-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $1,016.09 | 2019-2025 | |
| Emd Serono, INC. | $674.06 | 2019-2024 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $597.50 | 2023-2025 | |
| Genentech USA, INC. | $505.77 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Ani Pharmaceuticals, INC. | $332.02 | 2022-2025 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $94.18 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $88.24 | 2019-2024 | Ultomiris |
| Horizon Therapeutics Plc | $79.26 | 2022-2023 | Uplizna |
| Amgen INC. | $77.91 | 2024 | Uplizna |
| Abbvie INC. | $53.58 | 2023 | |
| Tanabe Pharma America, INC. | $49.84 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $25.62 | 2023 | Qelbree |
| Adlon Therapeutics L.P. | $21.81 | 2019 | |
| Argenx US, INC. | $19.89 | 2024 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Macaluso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.